推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733,021-34243363

chinasupport@letpub.com

登录 注册 新注册优惠

O Rachid, M Rawas-Qalaji, FER Simons… - AAPS PharmSciTech, 2011 - Springer
Received 22 December 2010; accepted 4 April 2011 Abstract. In the sublingual (SL) cavity, compared
with the gastrointestinal tract, tablets are subjected to minimal physiological agitation, and a limited
volume of saliva is available to facilitate disintegration and dissolution. None of the official ...
Related articles - All 2 versions
[HTML] from nih.govF Ibrahim, MKS El-Din, MI Eid… - Chemistry Central …, 2011 - ncbi.nlm.nih.gov
An accurate, simple, sensitive and selective reversed phase liquid chromatographic method
has been developed for the determination of ebastine in its pharmaceutical preparations. The
proposed method depends on the complexation ability of the studied drug with Zn 2+ ...
Cited by 1 - Related articles - All 4 versions
[HTML] from thelancet.itG Giovannoni, S Cook, K Rammohan… - The Lancet …, 2011 - Elsevier
On the basis of various clinical and MRI measurements, the phase 3 Cladribine Tablets Treating
Multiple Sclerosis Orally (CLARITY) study in patients with relapsing–remitting multiple sclerosis
(RRMS) showed that short-course oral treatment with cladribine at cumulative doses of ...
Cited by 4 - Related articles - All 5 versions
[HTML] from pediatricsdigest.mobiSH Kollins, R Jain, M Brams, S Segal… - …, 2011 - pediatricsdigest.mobi
RESULTS: Of 198 patients randomized, 102 received CLON-XR plus stimulant and 96 received
placebo plus stimulant. At week 5, greater improvement from baseline in ADHD Rating Scale
IV (ADHD-RS-IV) total score (95% confidence interval: −7.83 to −1.13; P = .009), ...
Cited by 2 - Related articles - All 4 versions
S Cook, P Vermersch, G Comi… - Multiple Sclerosis …, 2011 - msj.sagepub.com
... Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine
Tablets treating multiple sclerosis orallY) study. ... Results: Of the randomized patients, 88.6%
completed treatment with cladribine tablets versus 86.3% with placebo. ...
Cited by 3 - Related articles - All 3 versions
O Rachid, M Rawas-Qalaji, FER Simons… - AAPS PharmSciTech, 2011 - Springer
Received 22 December 2010; accepted 4 April 2011 Abstract. In the sublingual (SL) cavity, compared
with the gastrointestinal tract, tablets are subjected to minimal physiological agitation, and a limited
volume of saliva is available to facilitate disintegration and dissolution. None of the official ...
Related articles - All 2 versions
[HTML] from nih.govF Ibrahim, MKS El-Din, MI Eid… - Chemistry Central …, 2011 - ncbi.nlm.nih.gov
An accurate, simple, sensitive and selective reversed phase liquid chromatographic method
has been developed for the determination of ebastine in its pharmaceutical preparations. The
proposed method depends on the complexation ability of the studied drug with Zn 2+ ...
Cited by 1 - Related articles - All 4 versions
[HTML] from thelancet.itG Giovannoni, S Cook, K Rammohan… - The Lancet …, 2011 - Elsevier
On the basis of various clinical and MRI measurements, the phase 3 Cladribine Tablets Treating
Multiple Sclerosis Orally (CLARITY) study in patients with relapsing–remitting multiple sclerosis
(RRMS) showed that short-course oral treatment with cladribine at cumulative doses of ...
Cited by 4 - Related articles - All 5 versions
[HTML] from pediatricsdigest.mobiSH Kollins, R Jain, M Brams, S Segal… - …, 2011 - pediatricsdigest.mobi
RESULTS: Of 198 patients randomized, 102 received CLON-XR plus stimulant and 96 received
placebo plus stimulant. At week 5, greater improvement from baseline in ADHD Rating Scale
IV (ADHD-RS-IV) total score (95% confidence interval: −7.83 to −1.13; P = .009), ...
Cited by 2 - Related articles - All 4 versions
S Cook, P Vermersch, G Comi… - Multiple Sclerosis …, 2011 - msj.sagepub.com
... Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine
Tablets treating multiple sclerosis orallY) study. ... Results: Of the randomized patients, 88.6%
completed treatment with cladribine tablets versus 86.3% with placebo. ...
Cited by 3 - Related articles - All 3 versions

联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

© 2010-2024 中国: LetPub上海    网站备案号:沪ICP备10217908号-1    沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)

增值电信业务经营许可证:沪B2-20211595    网络文化经营许可证:沪网文[2023]2004-152号

礼翰商务信息咨询(上海)有限公司      办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室